ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 212 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q2 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $202 | -18.9% | 37,100 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $249 | -24.1% | 37,100 | 0.0% | 0.00% | -50.0% |
| Q1 2023 | $328 | +15.9% | 37,100 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $283 | -99.8% | 37,100 | +71.8% | 0.00% | +100.0% |
| Q3 2022 | $154,000 | -12.0% | 21,600 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $175,000 | -41.7% | 21,600 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $300,000 | -50.5% | 21,600 | 0.0% | 0.00% | -33.3% |
| Q4 2021 | $606,000 | -17.4% | 21,600 | 0.0% | 0.00% | -25.0% |
| Q3 2021 | $734,000 | -16.9% | 21,600 | 0.0% | 0.00% | -20.0% |
| Q2 2021 | $883,000 | +2.9% | 21,600 | +1.4% | 0.01% | 0.0% |
| Q1 2021 | $858,000 | -16.6% | 21,300 | +22.4% | 0.01% | -16.7% |
| Q4 2020 | $1,029,000 | +21.6% | 17,400 | 0.0% | 0.01% | 0.0% |
| Q3 2020 | $846,000 | -55.4% | 17,400 | -55.6% | 0.01% | -25.0% |
| Q2 2020 | $1,896,000 | – | 39,200 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 3,030,434 | $23,152,516 | 15.55% |
| BERYLSON CAPITAL PARTNERS, LLC | 289,726 | $2,213,507 | 6.45% |
| Matrix Capital Management Company, LP | 11,572,590 | $88,414,588 | 1.69% |
| Pier Capital, LLC | 1,012,401 | $7,734,744 | 1.27% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $229,151,929 | 1.15% |
| Eagle Health Investments LP | 607,860 | $4,644,050 | 1.07% |
| Triatomic Management LP | 130,805 | $999,350 | 0.84% |
| Aristotle Atlantic Partners, LLC | 1,880,567 | $14,367,532 | 0.80% |
| Senator Investment Group LP | 1,000,000 | $7,640,000 | 0.69% |
| ARK Investment Management | 9,201,245 | $70,297,512 | 0.61% |